TREVENA INC (TRVN)

US89532E2081 - Common Stock

0.46  0 (0%)

After market: 0.483 +0.02 (+5%)

News Image
3 months ago - Seeking Alpha

Trevena files to sell 2.78M shares for holders (NASDAQ:TRVN)

Trevena (TRVN) files prospectus for the resale of 2.78M shares of common stock by selling stockholders.

News Image
3 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!

News Image
3 months ago - Trevena, Inc.

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on...

News Image
3 months ago - Seeking Alpha

Trevena announces private placement and warrant exercise (NASDAQ:TRVN)

Trevena (TRVN) announces agreements for the sale of shares and warrants, expected to generate $4M in gross proceeds.

News Image
3 months ago - Trevena, Inc.

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the...

News Image
4 months ago - Trevena, Inc.

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked...

News Image
4 months ago - Trevena, Inc.

Trevena Awarded OLINVYK Agreement with Premier, Inc.

CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

News Image
4 months ago - Seeking Alpha

Trevena files for $200M mixed shelf (NASDAQ:TRVN)

Trevena (TRVN) files SEC prospectus to raise $200M through offering common stock, preferred stock, debt securities, and warrants.

News Image
5 months ago - Trevena, Inc.

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS...

News Image
5 months ago - Trevena, Inc.

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

Company to host a Conference Call & Webcast at 8:00 a.m. ET...

News Image
5 months ago - Trevena, Inc.

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events...

News Image
6 months ago - Trevena, Inc.

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the...

News Image
7 months ago - Seeking Alpha

Trevena gets $15M tranche after first commercial sale of OLINVYK in China (NASDAQ:TRVN)

Trevena (TRVN) has received a $15 million tranche under its non-dilutive ex-U.S

News Image
7 months ago - Trevena, Inc.

Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China ...

News Image
8 months ago - Trevena, Inc.

Trevena Reports Second Quarter 2023 Results and Provides Business Update

Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045...

News Image
8 months ago - Trevena, Inc.

Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

News Image
9 months ago - Trevena, Inc.

Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study

OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of...

News Image
10 months ago - Trevena, Inc.

Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical

$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive...

News Image
10 months ago - Seeking Alpha

Trevena regains compliance with Nasdaq listing rule (NASDAQ:TRVN)

Nasdaq has notified Trevena (TRVN) that the company has regained compliance with the minimum bid price requirement under Nasdaq listing rule.The Company maintained a minimum closing...

News Image
10 months ago - Trevena, Inc.

Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones

CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

News Image
11 months ago - Trevena, Inc.

Trevena Reports First Quarter 2023 Results and Provides Business Update

OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company...